<DOC>
	<DOCNO>NCT00663208</DOCNO>
	<brief_summary>The primary purpose study assess change Hepatitis C Virus RNA dose daclatasvir follow-up period subject chronic hepatitis C infection</brief_summary>
	<brief_title>A Multiple Ascending Dose Study Daclatasvir ( BMS-790052 ) Hepatitis C Virus Genotype 1 Infected Subjects</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<criteria>Chronically infect Hepatitis C Virus ( HCV ) genotype 1 Treatment naive treatment nonresponders treatment intolerant ; coinfected HIV Hepatitis B Virus HCV RNA viral load ≥10*5 IU/mL BMI 18 35kg/m² Any significant acute chronic medical illness stable control medication consistent Hepatitis C Virus infection HIV and/or HBV positive Major surgery within 4 week study drug administration gastrointestinal surgery could impact absorption study drug WOCBP enrol inpatient 16 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>